Filtered By:
Specialty: Research
Condition: Atrial Fibrillation
This page shows you your search results in order of date.
Order by Relevance | Date
Total 257 results found since Jan 2013.
Therapeutics of Extracellular Vesicles in Cardiocerebrovascular and Metabolic Diseases
Adv Exp Med Biol. 2023;1418:187-205. doi: 10.1007/978-981-99-1443-2_13.ABSTRACTExtracellular vesicles (EVs) are nanoscale membranous vesicles containing DNA, RNA, lipids, and proteins, which play versatile roles in intercellular communications. EVs are increasingly being recognized as the promising therapeutic agents for many diseases, including cardiocerebrovascular and metabolic diseases, due to their ability to deliver functional and therapeutical molecules. In this chapter, the biological characteristics and functions of EVs are briefly summarized. Importantly, the current state of applying EVs in the prevention and tr...
Source: Advances in Experimental Medicine and Biology - August 21, 2023 Category: Research Authors: Zhitao Hou Yiyan Lin Xinyu Yang Jing Chen Guoping Li Source Type: research
Ischemic stroke and systemic embolism among patients with non-valvular atrial fibrillation who abandon oral anticoagulant therapy
CONCLUSIONS: Patients with NVAF who abandoned the first DOAC fill had significantly higher risk of ischemic stroke/SE compared to patients who continued therapy beyond the first fill. There is an unmet need for better access to DOACs so that the long-term risk of poor outcomes may be minimized.PMID:37589313 | DOI:10.1080/03007995.2023.2247967
Source: Current Medical Research and Opinion - August 17, 2023 Category: Research Authors: Mark J Alberts Maryia Zhdanava Dominic Pilon Gabrielle Caron-Lapointe Patrick Lefebvre Brahim Bookhart Akshay Kharat Source Type: research
Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies
CONCLUSIONS: This systematic review supports findings from subgroup analyses of randomized controlled trials that, compared with warfarin, rivaroxaban is associated with generally neutral or positive effects on thrombosis and a mixed picture on bleeding outcomes in older adults with either NVAF or VTE treated in the United States.PMID:37584187 | DOI:10.1080/03007995.2023.2247988
Source: Current Medical Research and Opinion - August 16, 2023 Category: Research Authors: William L Baker Matthew S Roberts Youssef Bessada Kimberly S Caroti Veronica Ashton Brahim K Bookhart Craig I Coleman Source Type: research
Payer formulary tier increases of apixaban: how patients respond and potential implications
CONCLUSION: The majority of patients continued on apixaban despite higher OOP cost, suggesting patients' reluctance to change treatment for non-medical reasons; however, 30% of patients discontinued OAC treatment after higher apixaban tier placement.PMID:37519272 | DOI:10.1080/03007995.2023.2232636
Source: Current Medical Research and Opinion - July 31, 2023 Category: Research Authors: Steven Deitelzweig Emi Terasawa Nipun Atreja Amiee Kang Dionne M Hines Amol D Dhamane Melissa Hagan Ahmed Noman Xuemei Luo Source Type: research
Association between polymorphisms in Connexin40 Gene (Cx40) and risk of atrial fibrillation: a meta-analysis based on 3, 452 subjects
CONCLUSION: The Cx40 polymorphisms were positively associated with AF in both populations, especially on -44 polymorphism.PMID:37382580 | DOI:10.1080/1354750X.2023.2227361
Source: Biomarkers - June 29, 2023 Category: Research Authors: Zheng Lian Zheng Ma Zhi-Li Zhang Pei-Lin Liu Guo-Yong Zhang Cai-Xia Guo Source Type: research
